Invicta Diagnostic Share Price Today

Invicta Diagnostic subsidiary incorporates Porteus Pathogenius LLP

Invicta Diagnostic Limited's subsidiary, Porteus Medical LLP, incorporated Porteus Pathogenius LLP on 12 June, 2026, as a step-down subsidiary with a 51% stake acquired for ₹51,000. The new entity will focus on diagnostics and pathology services to expand the group's operations.

Invicta Diagnostic incorporates Porteus Pathogenius LLP as step-down subsidiary

Invicta Diagnostic Limited announced that its subsidiary, Porteus Medical LLP, has incorporated Porteus Pathogenius LLP as a step-down subsidiary with a 51% stake. The new entity will focus on diagnostics and healthcare services, with an initial capital contribution of ₹51,000 from Porteus Medical LLP.

Invicta Diagnostic reports FY26 income of INR33.04 crores

Invicta Diagnostic Limited reported a total income of INR33.04 crores for FY26, up from INR30.18 crores in FY25, with a net profit of INR4.87 crores. EBITDA increased to INR10.45 crores, and margins improved to 31.63%. The company invested INR12.96 crores in fixed assets, leading to higher depreciation. Expansion initiatives included new centers in Dadar, Pune, and Shegaon, and the acquisition of Vinchurkar Diagnostic in Nashik. Management remains focused on disciplined expansion in Maharashtra and exploring AI integration and overseas tele-radiology.

Invicta Diagnostic reports FY26 net profit of ₹48.73 Cr

Invicta Diagnostic Limited reported a consolidated net profit of ₹48.73 Cr for FY26, with total income rising to ₹330.42 Cr. EBITDA increased to ₹104.50 Cr, with a margin of 31.63%. The company invested ₹129.61 Cr in fixed assets and expanded its operations through new centres and acquisitions.

Invicta Diagnostic launches tele-radiology in US

Invicta Diagnostic Limited expanded its tele-radiology services to the United States on May 22, 2026. This launch marks the company's entry into the international market for diagnostic services. The move aims to enhance patient care through timely reporting and supports the company's global growth strategy.

Invicta completes 47% stake sale in Porteus Medical

Invicta Diagnostic Limited completed the sale of its 47% stake in Porteus Medical LLP on May 16, 2026, for a consideration of ₹47000. The subsidiary had a nil turnover in FY 2024-25 and a net worth of Rs. 1.25 Lakhs. The transaction does not require compliance with regulation 37A of the LODR Regulations.